Company: OSRH
Filing Date: 2025-01-31
Form Type: 424B3
Source: 0001213900-25-008874
Chunk: 181

Company: OSR Holdings, Inc.
Filing Date: 2025-01-31
Form: 424B3
Chunk 181
---
partyintermediaries to authorize, offer or provide, directly or indirectly, improper payments or benefits to recipients in the public or private sector. As we increase our international sales and business, we may engage with business partners and third -partyintermediaries to market our products and to obtain necessary permits, licenses, and other regulatory approvals. In addition, we or our third -partyintermediaries may have direct or indirect interactions with officials and employees of government agencies or state -ownedor -affiliatedentities. We could be held liable for the corrupt or other illegal activities of these third -partyintermediaries, our employees, representatives, contractors, partners, and agents, even if we do not explicitly authorize such activities. Various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain non -U.S. nationals, of information products classified for national security purposes, as well as certain products, technology and technical data relating to those products. If we expand our presence outside of the United States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside of the United States, which could limit our growth potential and increase our development costs. The failure to comply with laws governing international business practices may result in substantial civil and criminal penalties and suspension or debarment from government contracting. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA’s accounting provisions. Risks Related to the Development of New OSR Holdings’ Product Candidates The following risk factors reference the risks and uncertainties relating to the development of product candidates by OSR Holdings, which, following the closing of the Business Combination, will be the development of product candidates by New OSR Holdings. References in this section to “we,” “us,” and “our” refer to OSR Holdings prior to the closing of the Business Combination and to New OSR Holdings after closing. Our business includes subsidiaries that are developing oral immunotherapies for the treatment of cancer and design-augmented biologics. These companies have a limited operating history, and their programs are in early stages of development. This may make it difficult to evaluate our prospects and likelihood of success. Our business includes subsidiaries that are (i) developing oral immunotherapies for the treatment of cancer, and (ii) developing design -augmentedbiologics for age -relatedand other degenerative